linjc16/ctgov huggingface dataset:
Cardiac Speckle Tracking Myocardial Strain Balance

Study Overview
=================
Brief Summary
-----------------
The investigators intend to evaluate the function of left heart and right heart and the motion balance between four chambers of the heart by speckle tracking technique during the follow-up of patients with pulmonary hypertension, and explore the relationship between the balance and prognosis of patients.

Detailed Description
-----------------
Pulmonary hypertension is a fatal disease with progressive progressive vascular resistance that leads to the loss of right heart function. Right heart failure is the cause of death in most patients with end-stage pulmonary hypertension, and right heart function is also an important factor in determining the prognosis of patients. Echocardiography speckle tracking technology is a noninvasive technique for evaluating global and local cardiac function by tracking myocardial ultrasonic spots through computer image analysis technology and quantifying myocardial deformation. The investigators intend to evaluate the function of left heart and right heart and the motion balance between four chambers of the heart by speckle tracking technique during the follow-up of patients with pulmonary hypertension, and explore the relationship between the balance and prognosis of patients.

Official Title
-----------------
Cardiac Speckle Tracking Myocardial Strain Balance Method: a New Method to Evaluate the Effect of Pulmonary Hypertension on the Prognosis

Conditions
-----------------
Pulmonary Hypertension, Echocardiography

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with pulmonary hypertension by right cardiac catheterization The patient is between 18-80 years of age The date of diagnosis was from 2007 to 2017 Exclusion Criteria: Cardiomyopathy Severe complications Pregnancy Atrial fibrillation, or other irregular heart rhythm Poor ultrasonic image quality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| outcome | death or time out | one year |
Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

Study Overview
=================
Brief Summary
-----------------
The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.

Official Title
-----------------
Estimate of Costs Associated With Atrial Fibrillation Treatment With Rivaroxaban Versus Vitamin K Antagonists

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Drug: Rivaroxaban (Xarelto, BAY59-7939)
* Drug: Vitamin K antagonists (VKAs)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older than 18 years Diagnosis of non-valvular AF (ICD code 427.31) Pharmacological treatment with VKAs or rivaroxaban following diagnosis Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Treatment group with Rivaroxaban<br>Patients treated with Rivaroxaban | Drug: Rivaroxaban (Xarelto, BAY59-7939)<br>* As prescribed by treating physicians<br>|
| Control group with VKAs<br>Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%). | Drug: Vitamin K antagonists (VKAs)<br>* As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time in therapeutic range (TTR) values in the last 6 months |  | 6 months | 
| Presence of stroke | Presence of stroke prior and subsequent to treatment | 12 months | 
| Active substance received | Rivaroxaban or VKAs (Acenocoumarol and Warfarin) | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Date of stroke |  | 12 months | 
| Type of stroke | Type of stroke acccording to patients group: unknown, haemorrhagic or ischaemic. | 12 months | 
| Duration of treatment (in days) |  | 12 months | 
| Dose of the prescribed treatment |  | 12 months | 
| Frequency of the prescribed treatment (in hours) |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial fibrillation, VKA, Stroke
Comparison of Blood Pressure Throughout Pregnancy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to observe and analyze variation of diastolic blood pressure measurements at third trimester of pregnancy and when they present for delivery in comparison to healthy volunteers. When patients present for delivery, we expect blood pressure to be lower than normal. However this is not the case. We aim to determine where this trend occurs throughout to duration of pregnancy, and propose possible explanation as to the source of this event. After discharge, the information recorded includes each patient's blood pressure upon admission to the labor floor, and several blood pressure measurements from prior clinical visits.

Official Title
-----------------
Comparison of Blood Pressure Throughout Pregnancy

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females age 18-40 Parturients who present for delivery who are not yet in labor Exclusion Criteria: Patients with hypertension, cardiac disease, diabetes, or thyroid disorders Parturients who are already in labor upon presentation to the labor floor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurment of blood pressure throught pregnancy |  | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Condition: No specific disease is being studied, few procedures are excluded., Focus: To obtain blood pressure data and detect any trends to a statistically significant degree.
Long-Term Treatment of Collagenous Colitis With Budesonide

Study Overview
=================
Brief Summary
-----------------
The aim of the trial is to examine the effect of budesonide treatment on collagenous colitis. All patients is treated for 6 weeks with budesonide and thereafter randomised to 24 weeks treatment with placebo or continued budesonide. The end poit is effect on clinical symptoms (number of daily stools)

Official Title
-----------------
Long-Term Treatment of Collagenous Colitis With Budesonide. Prospective, Doubleblind Placebo-Controlled Trial.

Conditions
-----------------
Collagenous Colitis

Intervention / Treatment
-----------------
* Drug: Budesonide
* Procedure: sigmoidoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological criteria of Collagenous colitis Clinical activity (> 3 stools/day) Exclusion Criteria: Treatment of Collagenous colitis within the last 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks|
|Procedure: sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical symptoms |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Histological changes |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Collagenous colitis, Budesonide treatment, Diarrhea
Laparoscopic Colorectal Surgery For Cancer- Long Term Survival

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the survival after laparoscopic colectomies due to carcinoma.

Detailed Description
-----------------
Laparoscopic procedures for Colorectal Carcinoma are taking place in the modern era of surgery, It was not proven yet to show pure advantage over the open colectomies. These Procedures require highly skilled stuff with long learning curve, Financial sources,Increasing operation length. This retrospective study intends to show that the outcome of the overall survival is better in Laparoscopic patients. All data about patients who had laparoscopic colectomies due to carcinoma in Surgery A department in Souraski Medical Center was recorded prospectively since the operation day till discharge. The retrospective follow up will be collected from the outpatient clinic, the Oncology clinic and by questionnare to the patients. We wish to show that patients who were operated laparoscopy have better survival, better quality of life postoperatively.

Official Title
-----------------
Survival After Laparoscopic Colorectal Surgery

Conditions
-----------------
Colon Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adenocarcinoma of colon Exclusion Criteria: Non curative operation Non cancerous subjects
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Endoscopic Repair of Frontal Sinus CSF Leak

Study Overview
=================
Brief Summary
-----------------
This retrospective study was conducted on patients with frontal sinus leaks came to ENT departments of Al-Azhar University Hospital, New Damietta, Egypt, for a period of five years.

Detailed Description
-----------------
All patients in this study were evaluated during the follow-up period. Patients' age, sex, occupation, residence, and telephone number were recorded for each participant for demographic purposes. General and local examinations were also performed preoperatively as usual. Medical history, surgical approach, leakage site, complications, reconstruction technique, and follow-up were recorded. All cases were treated by endonasal endoscopy Complete sphenoethmoidectomy. Draf type IIa, IIb, and III according to defect location. Defect less than 3 mm closed by a plug of fat and facia lata or middle turbinate mucosa. Defect more than 3 mm closed by underlying facia lata, underlying cartilage, and overlay facia lata.

Official Title
-----------------
Outcome of the Endoscopic Repair of Frontal Sinus Cerebrospinal Fluid Leak

Conditions
-----------------
CSF Leakage

Intervention / Treatment
-----------------
* Procedure: Endonasal endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent endoscopic frontal sinus repair. Traumatic or spontaneous patients with a CSF leak at a minimum of six months not responding to conservative measures were included. Exclusion Criteria: Known malignancy or patients with frontal leak due to extensive tumor resection or intracranial injury

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Endonasal endoscopy|Complete sphenoethmoidectomy; Draf type IIa, IIb, and III according to defect location. Defect less than 3 mm closed by a plug of fat and facia lata or middle turbinate mucosa. Defect more than 3 mm closed by underlying facia lata, underlying cartilage, and overlay facia lata.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful treatment | Intracranial tension from 7-15 mmHg, No leakage, No complications | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications | Elevated intracranial tension, more than 15 mmHg, Fever, more than 37.5 degree, Meningitis | 1 week |
Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

Study Overview
=================
Brief Summary
-----------------
TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented. In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.

Official Title
-----------------
An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.

Conditions
-----------------
Solid Tumors

Intervention / Treatment
-----------------
* Biological: TB-403


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed malignity Measurable disease Performance status 1 or less (ECOG) Exclusion Criteria: Acute illness or infection Concurrent second malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Multiple IV doses of TB-403, an antibody directed against PlGF | Biological: TB-403<br>* Multiple IV<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of an anti-PlGF antibody |  | 85 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine multiple dose IV pharmacokinetics |  | 85 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
placental growth factor, monoclonal antibody, Phase I, solid tumors, Patients with solid tumors
Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesized that the CRP/troponin ratio measured in patients presenting to the ED with elevated troponin levels could differentiate between patients with cardiac ischemia and those who present due to a systemic inflammatory or infectious disease. The aim of the study was to determine the necessary CRP/troponin ratio required to rule out cardiac ischemia in a large ED population and determine its impact on long-term prognosis.

Official Title
-----------------
Increased C-reactive Protein Concentrations in Patients Admitted to the Emergency Department With Troponin Level Elevations Aids to Rule Out Coronary Ischemia

Conditions
-----------------
Myocardial Ischemia

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnosis of Myocardial Ischemia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted to the ED in the period 2016-2019 with cTn level higher than the 99th percentile of cTn concentration in the normal population (>0.014 nanogram/milliliter). Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Troponin-positive ED patients<br>All patients admitted to the ED at the Hillel Yaffe Medical Center in Hadera, Israel, in the period 2016-2019 with cTn level higher than the 99th percentile of cTn concentration in the normal population (>0.014 nanogram/milliliter). | Diagnostic Test: Diagnosis of Myocardial Ischemia<br>* Discharge diagnosis of myocardial ischemia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of the CRP/Troponin ratio | The accuracy of the CRP/Troponin ratio in ruling out of myocardial ischemia according to the diagnosis of ischemia/coronary intervention at discharge analyzed by standard statistical measures | Within 6 months |
A Comparison of Etomidate and Ketamine for Anesthesia Induction in Coronary Artery Bypass Graft Surgery

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine whether ketamine is an acceptable alternative to etomidate for anesthesia induction in coronary artery bypass graft surgery in terms of hemodynamic stability and also to compare these agents regarding their effect on adrenal gland steroid synthesis in these patients.

Conditions
-----------------
Coronary Artery Bypass Surgery

Intervention / Treatment
-----------------
* Drug: Ketamine
* Drug: Etomidate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for elective coronary artery bypass graft surgery with cardiopulmonary bypass Patient's written informed consent for study participation Ejection fraction ≥ 35% Exclusion Criteria: Allergy to study drugs Redo surgery

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ketamine<br> | Drug: Ketamine<br>* During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered<br>|
| Active Comparator: Etomidate<br> | Drug: Etomidate<br>* During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A more than 15% change in mean arterial pressure and heart rate after anesthesia induction |  | For 60 minutes after anesthesia induction | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adrenal gland steroid synthesis suppression | A less than 9 microgram/dl increase in serum cortisol after stimulation with adrenocorticotropic hormone | 24 hours and 5 days after study drug administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemodynamic stability, etomidate, ketamine, coronary artery bypass surgery after induction of anesthesia, hemodynamic stability
Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing In Vitro Fertilization Cycles

Study Overview
=================
Brief Summary
-----------------
Myo-Inositol (MI) is a precursors for the synthesis of phosphatidylinositol polyphosphates (PIPs). In male reproduction, it was shown that MI concentration in the seminiferous tubules is higher than in serum and it was increasing during the movement through the epididymis and the deferent duct. In the present study, the role of myo-inositol has been investigated as a possible antioxidant agent for the systemic treatment of male infertility and the improvement of the sperm's quality. Samples of seminal fluid were obtained from two groups of patients undergoing to a IVF cycle: healthy subjects and subjects with oligoasthenospermia (OA, < 15 mil/ml). The collected samples were submitted to optic microscopy in order to evaluate semen's volume, spermatozoa's number and motility, during the initial semen analysis and after density gradient separation method; these parameters were evaluated before and after the administration of 4000mg/die of myo-inositol associated to 400 µg of folic acid for three months. These values were compared with samples of seminal fluid of healthy patients undergoing to a IVF cycle for a female cause of infertility (control group).

Conditions
-----------------
Sperm Quality, Oligoasthenospermia

Intervention / Treatment
-----------------
* Dietary Supplement: myo-inositol + folic acid
* Dietary Supplement: myo-inositol + folic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3-5 days of sexual abstinence Exclusion Criteria: systemic and endocrine diseases genital infections history of cryptorchidism or varicocele microorchidism hormonal treatment in the last six months alcohol intake, cigarette smoke and/or drug abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Normospermic patients<br> | Dietary Supplement: myo-inositol + folic acid<br>* 4000mg myo-inositol + 400 µg folic acid<br>|
| Other: Oligoasthenospermic patients<br> | Dietary Supplement: myo-inositol + folic acid<br>* 4000mg myo-inositol + 400 µg folic acid<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Semen volume |  |  | 
| Spermatozoa count |  |  | 
| Spermatozoa progressive motility |  |  | 
| Number of spermatozoa after density gradient separation method |  |  |